ArticleIndian journal of ophthalmology2026
Rescue of conjunctival lymphatics after mitomycin C induced inhibition in rat eyes: An experimental study.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This experiment was designed to study the effect of mitomycin C (MMC) on conjunctival lymphatics and the lymphangiogenesis potential of synthetic retinoic acid (ec23) in rat eyes. This prospective animal experimental study included 30 Sprague-Dawley rats, and they were allocated into five groups. The right eye underwent localized subconjunctival surgical trauma with a 31-G needle, along with subconjunctival injection of either balanced salt solution, 0.01% MMC, 100 nM ec23, 0.01% MMC with 100 nM ec23, or 0.1% dimethyl sulfoxide in the right eye. The left eyes were control. Enucleation was done on post-operative day 14, and each conjunctival specimen was stained with Masson trichome, CD 31, and D2-40 to study fibrosis, vascular and lymphatic density, respectively. The main outcome measured was the density of conjunctival lymphatic vessels at the surgical site. It was noted that MMC resulted in a significant reduction in conjunctival lymphatic and vascular density in comparison with the control eyes (179 ± 21.33 vs 85 ± 30.82 and 190 ± 18.71 vs 85 ± 30.82 P = .009), whereas 100 nM ec23 caused significant increase in lymphatic vessel density in comparison with control eyes (310 ± 82.16 Vs 134 ± 32.09, P = .008). Similarly, 100 nM ec23 significantly increased conjunctival lymphatic density in 0.01% MMC-treated eyes (1000 ± 374.17 vs 388 ± 121.53, P = .016). Inter-group analysis showed that combined use of 100 nM ec23 caused the highest lymphatic (1000 ± 374.17, P = .001) and blood vessels (596 ± 294.67, P = .014) density. Masson trichome score (fibrosis) between intervention and control eyes was compared across different groups, and it was statistically insignificant. To conclude, MMC caused a significant reduction in lymphatic vessel density, and application of 100 nM ec23 resulted in significant lymphangiogenesis in both MMC-exposed and non-MMC-exposed eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.